Since the pandemic hit us everybody is waiting for the vaccine. The dream seems to be getting close to reality when Pharmaceutical giant Pfizer and German Biotech firm BioNTech told that they have developed a vaccine which can be 90% more effective to fight against coronavirus.
The data was recovered after the latest late-stage vaccine trial took place.
The trials were performed on people who were never in contact with the virus before. According to the vaccine, the first dose will be highly effective and protect the human body within 28 days. There will be 2 schedules of vaccine for prevention.
Previously formed vaccine laid out by White House coronavirus advisor Anthony Fauki has mentioned that up to 50-60% effectiveness would be acceptable for the vaccine while the newly formed vaccine is up to 90% more effective.
However, there are few complications that might vary after the final vaccine trial results will be analyzed.
Albert Bourla, CEO and Chairman at Pfizer, has mentioned that the first set of trials for the covid-19 vaccine in phase 3 has provided initial evidence in favor of the vaccine’s ability to prevent covid-19.
The cure for the covid-19 infection has been lurking for almost and here now. The data analyzed after the conducted trials were based on analysis after 94 participants’ data was analyzed and that they contracted the virus and the findings will continue 164 cases have been contracted.
The Biotech firm and Pharmaceutical giant are currently working on there vaccine to produce up to 50 million doses in 2020 and kick start the next year with 1.3 billion vaccines available to people.
The data on the Phase III trial with be submitted for scientific review in a precise manner with the subsequent submission and after the 2 months’ data is compiled, the company has planned to submit their work for emergency use authorization to the US Food and Drug Administration.
To help the world combat such infection a couple tried all the capabilities and invested their entire time devoting to the Corona Virus Vaccine.
Ugur Sahin and Oezlem Tuereci, the couple who are the sole barriers of the building the vaccine which is op to 90% effective.
The research started soon after the covid-19 cases started spreading in January or before that and the 55-year-old physician dealt with a staff of 500 people to work on possible several compounds.
In March, during the lockdown, Sahin focused on BioNTech, developed 20 Vaccine Candidate, and found that the mRNA technology-based Technology has trimmed down to promising opinions and options by building BNT162b2 vaccine.
About 38,955 participants out of total enrolled people list of 43,538 people, the clinical trials were recorded with the second dose of vaccine. The trials of phase 3 of mRNA based vaccine soon started on July 27.
When the data is analyzed and necessary safety manufacturing data has been prepared through the clinical trials and as soon as the safety milestone is achieved, most probably in the third week of November, the data will be submitted.